Press Release

February 26, 2014
Verastem to Present at Upcoming Scientific Conferences

-Results from a Phase 1 study of VS-6063 in Japanese patients to be announced-

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 26, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will present at two upcoming scientific conferences, including the 12th International Congress on Targeted Anticancer Therapies (TAT), where a poster with data from a Phase 1 trial of VS-6063 (defactinib), a potent inhibitor of focal adhesion kinase (FAK), in Japanese patients with advanced solid tumors will be presented. The presentation details are as follows:

 

12th International Congress on Targeted Anticancer Therapies on Wednesday, March 5, 2014 at the Capitol Hilton in Washington, D.C.

 

Abstract Title: Addressing the Drug Lag in Japan: A Phase 1 Study of Defactinib in Japanese Subjects to Facilitate Multiregional Clinical Trials

Abstract Code: P6.1

Date and Time: Wednesday, March 5 at 6 PM, during Welcome Reception & Posterviewing

Session: P6

 

4th International Conference on Tumor Progression and Therapeutic Resistance on Monday, March 10, 2014 at the Omni Parker Hotel in Boston, MA

 

Presentation Title: Cancer Stem Cells as Potential Sources of Therapeutic Resistance

Presenter: Robert Weinberg, Ph.D., Professor, Massachusetts Institute of Technology, Whitehead Institute of Biomedical Research and Verastem co-founder and Chair of Scientific Advisory Board

Date and Time: Monday, March 10 at 10:15 AM

Session: 2

Session Title: Cancer Stem Cells/Tumor Heterogeneity

 

Presentation Title: Development of Small Molecule Inhibitors of FAK and P13K/mTOR that Preferentially Target Cancer Stem Cells

Presenter: Jonathan Pachter, Ph.D., Verastem Head of Research

Date and Time: Monday, March 10 at 5:00 PM

Session: 4

Session Title: Personalized/Targeted Therapeutics

 

About VS-6063

VS-6063 is an orally available compound designed to target cancer stem cells through the potent inhibition of focal adhesion kinase (FAK). Cancer stem cells are an underlying cause of tumor resistance to chemotherapy, recurrence and ultimate disease progression. Research by Robert Weinberg, Ph.D., scientific cofounder and chair of Verastem’s Scientific Advisory Board, and Verastem has demonstrated that the FAK pathway is critical for the growth and survival of cancer stem cells. VS-6063 is currently being studied in the registration-directed COMMAND trial in mesothelioma (www.COMMANDmeso.com), a Phase 1/1b study in combination with paclitaxel for patients with ovarian cancer, a Phase 1 study in Japan in patients with advanced solid tumors and a Phase 2 trial in patients with Kras-mutated non-small cell lung cancer. VS-6063 has been granted orphan drug designation in the U.S. and E.U. for use in mesothelioma.

About Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com.

Forward-looking statements:

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Source: Verastem, Inc.

Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com